<DOC>
	<DOCNO>NCT01728805</DOCNO>
	<brief_summary>The purpose study compare progression free survival KW-0761 versus vorinostat subject relapse refractory CTCL .</brief_summary>
	<brief_title>Study KW-0761 Versus Vorinostat Relapsed/Refractory CTCL</brief_title>
	<detailed_description>Phase 3 randomize study compare progression free survival subject relapsed/refractory CTCL receive KW-0761 versus receive vorinostat . Subjects progress vorinostat allow cross KW-0761 upon progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Males female subject ≥ 18 year age time enrollment , except Japan subject must ≥ 20 year age time enrollment Histologically confirm diagnosis mycosis fungoides ( MF ) Sezary Syndrome ( SS ) Stage IB , IIA , IIB , III IV Subjects fail least one prior course systemic therapy . Psoralen plus ultraviolet light therapy ( PUVA ) consider systemic therapy Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 1 study entry Resolution clinically significant toxic effect prior cancer therapy grade ≤1 National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCICTCAE , v.4.0 ) Adequate hematological , renal hepatic function Subjects previously treat antiCD4 antibody alemtuzumab eligible provide CD4+ cell count ≥ 200/mm3 Subjects mycosis fungoides ( MF ) know history noncomplicated staphylococcus infection/colonization eligible provide continue receive stable dos prophylactic antibiotic Women childbearing potential ( WOCBP ) must negative pregnancy test within 7 day receive study medication WOCBP male subject well female partner childbearing potential must agree use effective contraception throughout study Prior treatment KW0761 vorinostat . Large cell transformation . However , subject history LCT without current aggressive disease current evidence LCT pathology skin lymph node would eligible . Diagnosed malignancy past two year . However , subject nonmelanoma skin cancer , melanoma situ , localized cancer prostate current PSA &lt; 0.1 ng/mL , treat thyroid cancer cervical carcinoma situ ductal/lobular carcinoma situ breast within past two year may enroll long current evidence disease . Clinical evidence central nervous system ( CNS ) metastasis . Psychiatric illness , disability social situation would compromise subject 's safety ability provide consent , limit compliance study requirement . Significant uncontrolled intercurrent illness Known test positive human immunodeficiency virus ( HIV ) , human Tcell leukemia virus ( HTLV1 ) , hepatitis B hepatitis C. Active herpes simplex herpes zoster . Subjects prophylaxis herpes start take medication least 30 day prior study entry , active sign active infection , whose last active infection 6 month ago , may enter study , continue take prescribed medication duration study . Experienced allergic reaction monoclonal antibody therapeutic protein . Known active autoimmune disease exclude . ( For example , Grave 's disease ; systemic lupus erythematosus ; rheumatoid arthritis ; Crohn 's disease ; psoriasis ) . Is pregnant ( confirm beta human chorionic gonadotrophin [ βHCG ] ) lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cutaneous T-Cell Lymphoma ( CTCL )</keyword>
	<keyword>myocis fungoides ( MF )</keyword>
	<keyword>Sezary Syndrome ( SS )</keyword>
</DOC>